ClinicalTrials.gg
WithdrawnNCT05494619Updated Dec 15, 2022

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)

A Phase 3 interventional study of Crovalimab and Placebo in Guillain-Barré Syndrome, sponsored by Hoffmann-La Roche. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-15.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Why this study was withdrawn
This study has been withdrawn due to an internal decision. The decision was not due to any safety concerns with study drug.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of crovalimab compared with placebo as an add-on therapy to intravenous immunoglobulin (IVIg) in participants with severe GBS.

02

Conditions studied

  • Guillain-Barré Syndrome
03

In context

Guillain-Barre Syndrome

98 studies on the registry are indexed under Guillain-Barre Syndrome; 30 are open to participants now.

Browse Guillain-Barre Syndrome studies →

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight >= 40 kg at screening
  • Confirmed diagnosis of GBS according to National Institute of Neurological Disorders and Stroke (NINDS) classification system
  • Onset of weakness due to GBS within 2 weeks before randomization
  • Able to start the first dose of blinded study drug within 2 weeks of onset of weakness
  • Able to climb a flight of stairs prior to GBS
  • Unable to walk independently for >=10 meters (FG >=3) with deteriorating weakness as per investigator judgment, or FG 4 or FG 5 on the GBS-DS. These criteria must be satisfied during screening.
  • Undergoing or starting IVIg treatment (400 mg/kg QD for 5 days) prior to first blinded study drug administration. Participants must be able to receive the first dose of blinded study drug before the final dose of IVIg during the 5-day period of IVIg treatment.
  • A record of vaccination (\<=3 years) against Neisseria meningitidis, Haemophilus influenzae type B, and Streptococcus pneumonia prior to initiation of blinded study drug, in accordance with most current local guidelines as applicable for patients with complement deficiency.
  • Adequate hepatic and renal function
  • For female participants of : agreement to remain abstinent (refrain from heterosexual intercourse) or use during the treatment period and for up to 11 months after the final dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Clear clinical and historical evidence of significant or disabling acute or chronic peripheral neuropathy of alternative etiology, chronic inflammatory demyelinating polyneuropathy, severe vitamin deficiency, porphyria, or diagnosis of Charcot Marie Tooth disease or other genetic neuropathy
  • History of requiring a permanent aid to walk prior to GBS
  • Treatment with plasmapheresis or PLEX after GBS diagnosis, or a plan to receive this treatment
  • Receipt of systemic treatment within 4 weeks prior to randomization
  • Known or suspected hereditary complement deficiency
  • Known or suspected immune deficiency
  • Recent use (up to five half-lives) of treatment with complement inhibitors (e.g., 10 weeks for eculizumab, 41 weeks for ravulizumab)
  • History of Neisseria meningitidis infection within 12 months prior to screening and up to first blinded study drug administration (Day 1)
  • that would prevent use of any class of antibiotics as Neisseria meningitides prophylaxis
  • Immunization with a within 1 month before first blinded study drug administration (Day 1)
  • Participants who have been partially or fully vaccinated against SARS-CoV-2 with a locally approved vaccine are eligible to be enrolled in the study, 3 days or longer after inoculation.
  • Recent SARS-CoV-2 infection (defined by a positive PCR test within the 2-week period prior to screening), or ongoing symptoms of active COVID-19
  • Any systemic bacterial, viral, or fungal infection ongoing at screening and up to the first blinded study drug administration (Day 1) which, in the investigators' judgment, is active and could potentially be worsened by immunosuppression
  • Current , , or infection
  • History of within 5 years prior to screening and up to the first blinded study drug administration (Day 1)
  • History of , allergic, or anaphylactic reactions to crovalimab or IVIg, including hypersensitivity to human, humanized, or murine monoclonal antibodies, or known hypersensitivity to any constituent of the products
  • For participants with prior exposure to anti-CD20 agents, most recent anti-CD20 treatment within 6 months prior to screening
  • Substance abuse within 12 months prior to screening, in the investigator's judgment
  • Active suicidal ideation within 6 months prior to screening or history of suicide attempt within 3 years prior to screening
  • Concurrent disease, treatment, procedure or surgery, or abnormality in clinical laboratory tests that could interfere with the conduct of the study, may pose any additional risk for the patient, or would, in the opinion of the investigator, preclude the patient's safe participation in and completion of the study
  • Participation in another interventional treatment study with an agent or use of any experimental therapy within 28 days of screening or within five half-lives of that investigational product, whichever is longer
  • Splenectomy \<= 6 months prior to screening
  • Selective IgA deficiency with development of antibodies to IgA
  • Only applicable for participants receiving proline-containing IVIg products: History or ongoing hyperprolinaemia type I or II at screening
  • Only applicable for participants receiving sucrose/glucose/maltose-containing IVIg products: History of or ongoing diabetes mellitus or use of concomitant nephrotoxic medications
  • Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 11 months after the final dose of crovalimab.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Crovalimab

    Participants will receive a single intravenous (IV) infusion of crovalimab on Day 1 based on body weight, followed by crovalimab subcutaneous (SC) injection on Days 2, 8, 15, and 22 for a total of 4 weeks. Additionally, intravenous immunoglobulin (IVIg) background therapy will be administered once a day (QD) for 5 days.

    Drug: Crovalimab · Drug: Intravenous immunoglobulin therapy

  • Placebo comparator
    Placebo

    Participants will receive a single IV infusion of placebo on Day 1 based on body weight, followed by placebo SC injections on Days 2, 8, 15, and 22 for a total of 4 weeks. Additionally, IVIg background therapy will be administered QD for 5 days.

    Drug: Placebo · Drug: Intravenous immunoglobulin therapy

Interventions

  • Crovalimab will be administered at a dose of 1000 milligrams (mg) IV (for participants with body weight ≥ 40 kilograms (kg) and \<100 kg) or 1500 mg IV (for participants with body weight ≥ 100 kg) on Day 1, followed by crovalimab 340 mg SC injections on Days 2, 8, 15 and 22 in all participants.

  • DrugPlacebo

    Placebo will be administered IV on Day 1 at a dose of 1000 mg for participants with body weight ≥ 40 kg to \< 100 kg, or 1500 mg for participants with body weight ≥ 100 kg. It will be administered SC on Days 2, 8, 15, and 22 at a dose 340 mg in all participants.

  • All participants will receive background therapy of IVIg at a dose of 400 milligrams/kilograms (mg/kg) QD for 5 days.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants who Reach Hughes Functional Grade (FG) Score ≤ 1 on the Guillain-Barré Syndrome Disability Scale (GBS-DS) at Week 24

    The Guillain-Barré Syndrome disability score (GBS DS) is used to assess the degree of functional disability of study participants. The scale consists of seven grades of functional disability ranging from 0 (healthy with no symptoms attributable to GBS) to 6 (death).

    Time frame: Week 24

Secondary outcomes

  1. Time to Recover Independent Walking Assessed Using the 10-Meter Walk Test (10-MW)

    Defined as time from randomization to the first time point at which the participant is able to walk independently, assessed using the 10-MWT.

    Time frame: Up to approximately 52 weeks

  2. Functional Outcome on GBS-DS at Week 8

    The Guillain-Barré Syndrome disability score (GBS DS) is used to assess the degree of functional disability of study participants. The scale consists of seven grades of functional disability ranging from 0 (healthy with no symptoms attributable to GBS) to 6 (death).

    Time frame: Week 8

  3. Percentage of Inflammatory Rasch-Built Overall Disability Scale (I-RODS) Responders at Week 24

    Defined as a participant who is able to perform all activities assessed by the I-RODS with or without some difficulties (graded 1 or 2). I-RODs is a 24-item scale to rate a participant's general ability to function and complete activities of daily living. The items range in difficulty from very easy ("reading a newspaper/book" and "eating") to very difficult ("standing for hours" and "running"). The participant assigns a score between 0 and 3 (0: not possible, 1: possible with difficulty, 2: possible without any difficulty, 3: unable to perform before GBS \[option 3 only available at the baseline visit\]) to each item.

    Time frame: Week 24

  4. Mean Post-Recovery Time

    Defined as the time from reaching FG ≤ 1 for the first time after randomization to Week 24

    Time frame: Randomization to Week 24

  5. Duration of Ventilator Support

    Time frame: Randomization to Week 24

  6. Percentage of Participants with Treatment Emergent Adverse Events

    Adverse events severity was determined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0) grading

    Time frame: Up to approximately 52 weeks

  7. Percentage of Participants with Treatment Emergent Adverse Events Leading to Study Drug Discontinuation

    Time frame: Up to approximately 52 weeks

  8. Percentage of Participants with Anti-Drug Antibodies to Crovalimab

    Time frame: Up to approximately 52 weeks

  9. Serum Concentrations of Crovalimab

    Time frame: From Day 1 up to Week 52

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2022; primary completion for Mar 2026, 39 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2022
First posted
Aug 10, 2022
StartEst.
Nov 30, 2022
Primary completionEst.
Mar 19, 2026
CompletionEst.
Sep 30, 2026
Last update
Dec 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05494619
Lead sponsor
Hoffmann-La Roche
Collaborators
Chugai Pharmaceutical Co., Ltd. (Sponsor in Taiwan and Japan)
Responsible party
Sponsor
First posted
Aug 10, 2022
Start date
Nov 30, 2022 (estimated)
Primary completion
Mar 19, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Dec 15, 2022

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crovalimab

Start the discussion